

RECEIVED
CENTRAL FAX CENTER

NOV 01 2004

PATENT

Practitioner's Docket No. 700157-48012-RCE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: David E. Fisher

Application No.: 09/229,283 Group No.: 1642
Filed: 01/13/99 Examiner: UNGAR, Susan
For: USE OF MICROPHTHALMIA FOR DIAGNOSIS, PROGNOSIS AND/OR
TREATMENT OF MELANOMA

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following papers are being facsimile transmitted to the Patent and Trademark Office at (703) 872-9306 (official fax number) and to Susan Ungar at (571) 273-0837 on the date shown below:

1. Certification of Facsimile Transmission (1 pg.);
2. Transmittal Form (1 pg.); and
3. Supplemental Amendment (4 pp.).

October 28, 2004
Date


Linda M. Ginsberg


Signature

Certification of Facsimile Transmission—page 1 of 1

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/229,283
	Filing Date	January 13, 1999
	First Named Inventor	David E. Fisher
	Art Unit	1642
	Examiner Name	UNGAR, Susan
	Attorney Docket Number	700157-48012-RCE
Total Number of Pages in This Submission		

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/Declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Certification of Facsimile Transmission and Return Receipt Postcard
Remarks The Commissioner is hereby authorized to charge any fee deficiency or credit any overpayment to the Nixon Peabody LLP Deposit Account No. 50-0850.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	Nixon Peabody LLP, 100 Summer Street, Boston, MA 02110	
Signature		
Printed name	Ronald I. Eisenstein	
Date	10/28/04	Reg. No. 30,628

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:		
Signature		
Typed or printed name	Linda M. Ginsberg	Date 10/28/2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Attorney Docket No.: 700157-48012

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: David E. Fisher

EXAMINER: S. Ungar


SERIAL NO.: 09/ 229,283

GROUP: 1642

FILED: January 13, 1999

RECEIVED
CENTRAL FAX CENTER
NOV 01 2004

FOR: USE OF MICROPHTHALMIA FOR DIAGNOSIS, PROGNOSIS AND/OR
TREATMENT OF MELANOMA

CERTIFICATE OF FACSIMILE (37 C.F.R. SECTION 1.8(a))	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being sent via facsimile on the date shown below to the MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450	
Date <u>10/28/04</u>	<div>Linda M. Ginsberg <small>(type or print name of person mailing paper)</small></div> <div> <small>Signature of person mailing paper</small></div>

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL AMENDMENT

Dear Sir:

Supplemental to the Amendment filed August 18, 2004, Applicant is submitting this amendment.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 4 of this paper.

BOS1430939.1